TRCT
REVB icon

Tower Research Capital (TRC)’s Revelation Biosciences REVB Stock Holding History

Tower Research Capital (TRC)’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.72K Buy
6,528
+2,454
+60% +$2.66K ﹤0.01% 4187
2026
Q1 		$4.89K Buy
+4,074
New +$7.88K ﹤0.01% 4161
2025
Q4 		– Sell
-134
Closed -$758 – 5509
2025
Q3 		$758 Sell
134
-156
-54% -$1.51K ﹤0.01% 4951
2025
Q2 		$2.61K Buy
290
+120
+71% +$3.14K ﹤0.01% 4624
2025
Q1 		$5.37K Buy
170
+157
+1,208% +$8.77K ﹤0.01% 4127
2024
Q4 		$1.17K Hold
13
– – ﹤0.01% 5076
2024
Q3 		$2.16K Sell
13
-13
-50% -$3.13K ﹤0.01% 5040
2024
Q2 		$9.56K Buy
26
+10
+63% +$4.13K ﹤0.01% 4228
2024
Q1 		$8.54K Buy
+16
New +$19.3K ﹤0.01% 4004
2023
Q4 		– Hold
0
– – – 5422
2023
Q3 		– Hold
0
– – – 5302
2023
Q2 		– Hold
0
– – – 5486
2023
Q1 		– Hold
0
– -$2K – 6199
2022
Q4 		– Hold
0
– – – 5413
2022
Q3 		– Hold
0
– – – 5604
2022
Q2 		– Hold
0
– – – 4947
2022
Q1 		– Hold
0
– – – 5242
2021
Q3 		– Hold
0
– -$1K – 6099
2021
Q2 		– Hold
0
– – – 5242

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Tower Research Capital (TRC)'s REVB Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Revelation Biosciences (REVB) stake by 60% in Q2 2026, buying an estimated $2.66K and bringing the position to 6,528 shares worth $6.72K. The position accounts for ﹤0.01% of the portfolio, ranked #4187.

Tower Research Capital (TRC) first reported a position in REVB in Q1 2024 and has held it in 9 quarters since. The position peaked at $9.56K in Q2 2024. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • Tower Research Capital (TRC) held 6,528 shares of Revelation Biosciences worth $6.72K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,454 Revelation Biosciences shares in Q2 2026, an estimated $2.66K.
  • Revelation Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4187 holding.
  • Tower Research Capital (TRC) first reported a position in Revelation Biosciences in Q1 2024 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Revelation Biosciences position peaked at $9.56K in Q2 2024.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.